RAD51C Antibody

Code CSB-PA003917
Size US$167Purchase it in Cusabio online store
(only available for customers from the US)
  • Western Blot analysis of COS7 cells using Rad51C Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No. O43502
Target Names RAD51C
Alternative Names BROVCA3 antibody; DNA repair protein RAD51 homolog 3 antibody; FANCO antibody; MGC104277 antibody; R51H3 antibody; RA51C_HUMAN antibody; Rad 51C antibody; RAD51 homolog C (S. cerevisiae) antibody; Rad51 homolog c (S. cerevisiae), isoform CRA_b antibody; RAD51 homolog C antibody; RAD51 like protein 2 antibody; RAD51 paralog C antibody; RAD51, S. cerevisiae, homolog of, C antibody; RAD51-like protein 2 antibody; RAD51C antibody; RAD51C protein antibody; RAD51L2 antibody; RAD51L2/RAD51C protein antibody; RGD1563765 antibody; Yeast RAD51 homolog 3 antibody
Raised in Rabbit
Species Reactivity Human,Monkey
Immunogen Synthesized peptide derived from the Internal region of Human Rad51C.
Immunogen Species Homo sapiens (Human)
Conjugate Non-conjugated
Isotype IgG
Purification Method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form Liquid
Tested Applications WB, IHC, IF, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
IF 1:200-1:1000
ELISA 1:5000
Protocols Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Background

(From Uniprot)
Essential for the homologous recombination (HR) pathway of DNA repair. Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Part of the RAD21 paralog protein complexes BCDX2 and CX3 which act at different stages of the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 seems to act downstream of BRCA2 recruitment and upstream of RAD51 recruitment; CX3 seems to act downstream of RAD51 recruitment; both complexes bind predominantly to the intersection of the four duplex arms of the Holliday junction (HJ) and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. The BCDX2 subcomplex RAD51B
Gene References into Functions
  1. results increase our knowledge about the RAD51C and RAD51D mutation spectrum and support the notion that these genes should be included in the gene panel testing performed on patients with hereditary breast and ovarian cancer syndrome PMID: 29409816
  2. The authors assessed whether RAD51C promoter hypermethylation like mutation was associated with increased survival or increased sensitivity to platinum chemotherapy. However the results showed that neither outcomes were met PMID: 29233532
  3. novel splice-site mutations affect the last nucleotide of exon 2 (c.404G>C, c.404G>T) and disrupt proper RAD51C pre-mRNA processing. PMID: 27622768
  4. We showed that the mutation frequency of RAD51C in Japanese familial breast cancer cases was similar to that in Western countries and that the prevalence of deleterious mutation of PALB2 was possibly lower. Furthermore, our results suggested that BRIP1 mutation frequency in Japan might differ from that in Western countries PMID: 28796317
  5. Here we report yet another example of a rare RAD51C missense change (p.Arg312Trp) that impairs protein function. PMID: 28829762
  6. Using the human mammary epithelial cell line MCF10A, we show that deletion of TP53 can rescue RAD51C-deficient cells from radiation-induced cellular senescence, whereas it exacerbates their centrosome amplification and nuclear abnormalities PMID: 26820992
  7. Results identified a chromosomal translocation between Rad51C and Ataxin-7 in colorectal tumors. The in-frame fusion transcript results in a fusion protein with molecular weight of 110 KDa. In vitro 5-Azacytidine treatment of colorectal tumor cells showed expression of the fusion gene is regulated by promoter methylation. PMID: 27296891
  8. Germline mutation in RAD51C gene is associated with neoadjuvant therapy response in triple negative breast patients. PMID: 27328445
  9. Germline RAD51C mutation was found in patients with hereditary and sporadic gastric cancer. PMID: 28024868
  10. individuals with mutations in RAD51C that are exposed to estrogen would be more susceptible to accumulation of DNA damage, leading to cancer progression. PMID: 27753535
  11. Overexpression of RAD51C is associated with resistance to cisplatin and radiation in non-small cell lung cancer. PMID: 27465554
  12. RAD51C mutations were identified in 0.5 % of Danish families. PMID: 26740214
  13. RAD51C mutation is not associated with high-risk patients from Serbian hereditary breast/ovarian cancer. PMID: 26406419
  14. a mutation analysis in 171 high-risk BRCA1 and BRCA2 negative ovarian cancer patients, to evaluate the frequency of hereditary RAD51C and RAD51D variants in Czech population, is reported. PMID: 26057125
  15. Novel Rad51C splice variants occur in colorectal tumors and cells: Variant 1 without exon-7, Variant 2 without exon 6 and 7 , or Variant 3 without exon 7 and 8. They are associated with FANCD2 foci positive colorectal tumors and microsatellite stability. PMID: 25669972
  16. conclude that the woman has two potential disease-causing mutations and that predictive testing of family members should include both the RAD51C and BRCA2 mutation PMID: 25154786
  17. RAD51C and RAD51D are moderate ovarian cancer susceptibility genes. PMID: 26261251
  18. RAD51C mutation is associated with breast and ovarian cancer. PMID: 25086635
  19. The effect of common single nucleotide polymorphisms (SNPs) in non-coding regions of RAD51C in modulating the risk of breast cancer was investigated. PMID: 25343521
  20. Mutations in RAD51C are associated with drug resistance in breast cancer. PMID: 25292178
  21. the Rad51C promoter fragment can be used to transcriptionally target cancer cells. PMID: 24742710
  22. The findings suggest that RAD51C plays a marginal role in breast and ovarian cancer predisposition in Pakistan. PMID: 24800917
  23. three different cancer susceptibility and FA proteins function in a DNA repair pathway based upon the PALB2 WD40 domain binding to RAD51C and BRCA2. PMID: 24141787
  24. Paralogs of RAD51 might be candidates for genetic risk factors in sporadic squamous cell carcinomas of the head and neck. PMID: 24315737
  25. Single nucleotide polymorphisms in the Rad51C gene are strongly associated with increased risk for developing head and neck cancer. PMID: 24631219
  26. RAD51C-deficient cancer cells are highly sensitive to olaparib and offer preclinical proof-of-principle that RAD51C deficiency may be considered a biomarker for predicting the antitumor effects of olaparib. PMID: 23512992
  27. RAD51C is a susceptibility gene for ovarian and BC. PMID: 22725699
  28. Study observed centrosome defects in the absence of XRCC3. While RAD51B and RAD51C act early in homologous recombination, XRCC3 functions jointly with GEN1 later in the pathway at the stage of Holliday junction resolution. PMID: 23108668
  29. No RAD51C mutations c.837 + 1G > A or c.93delG were detected. PMID: 23176254
  30. This study concludes that germline mutations in RAD51C contribute marginally to breast and ovarian cancer susceptibility in ethnically diverse, Jewish high risk families. PMID: 23117857
  31. RAD51C mutations are rare events among high-risk breast cancer and breast/ovarian cancer families. PMID: 22476429
  32. We propose that analogous to germline genetic mutations constitutive epimutations in BRCA1 and RAD51C may serve as the first hit of tumor development. PMID: 22843497
  33. study detected 1.3 percent mutations of RAD51C in breast and ovarian cancer families, while mutations in breast cancer only families seem to be very rare PMID: 22451500
  34. the contribution of RAD51C and RAD51D gene mutations to an inherited high risk of ovarian cancer is very small PMID: 22752287
  35. RAD51C germline mutations in families with a history for both breast and ovarian cancer appear to have a low prevalence with the exception of some founder mutations. PMID: 22370629
  36. Missense variant of RAD51C (p.Gly264Ser) is a moderate penetrance allele in high-risk breast and ovarian cancer families. PMID: 21990120
  37. unravel the critical role of RAD51C in the FA pathway of ICL repair and as a tumor suppressor. PMID: 22167183
  38. RAD51C mutations are implicated in breast and ovarian cancer predisposition. PMID: 21750962
  39. RAD51C is a rare breast and ovarian cancer susceptibility gene. PMID: 21980511
  40. PALB2 mutations are present in a small but substantial proportion of inherited breast cancer cases, and indicates that RAD51C at a population level does not account for a substantial number of familial breast cancer cases PMID: 21409391
  41. These results suggest RAD51C as the first moderate-to-high risk susceptibility gene for ovarian cancer. PMID: 21616938
  42. Data show there was no deleterious RAD51C mutation among the 454 familial breast/ovarian cancer patients. PMID: 20723205
  43. Unable to confirm the contribution of the RAD51C gene to hereditary breast and ovarian cancer. PMID: 20697805
  44. Reports show RAD51C is a cancer susceptibility gene associated with increased risk of Fanconi anemia-like disorder, breast and ovarian cancer.[Review] PMID: 20952512
  45. biallelic germline mutations in a RAD51 paralog are associated with an FA-like syndrome [case report] PMID: 20400963
  46. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene PMID: 20400964
  47. This work describes the in vitro and in vivo identification of the RAD51B/RAD51C heterocomplex PMID: 11744692
  48. Rad51B and Rad51C function through interactions with the human Rad51 recombinase and play a crucial role in the homologous recombinational repair pathway PMID: 12427746
  49. analysis of protein domains important for functioning of RAD51L2; there is a specific requirement for RAD51L2 in gene conversion in mammalian cells PMID: 12966089
  50. a fragment of Rad51B containing amino acid residues 1-75 interacts with the C-terminus and linker of Rad51C, residues 79-376, and this region of Rad51C also interacts with mRad51D and Xrcc3 PMID: 14704354

Show More

Hide All

Involvement in disease Fanconi anemia complementation group O (FANCO); Breast-ovarian cancer, familial, 3 (BROVCA3)
Subcellular Location Nucleus, Cytoplasm, Cytoplasm, perinuclear region, Mitochondrion
Protein Families RecA family, RAD51 subfamily
Tissue Specificity Expressed in a variety of tissues, with highest expression in testis, heart muscle, spleen and prostate.
Database Links

HGNC: 9820

OMIM: 602774

KEGG: hsa:5889

STRING: 9606.ENSP00000336701

UniGene: Hs.412587


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1